| Literature DB >> 34836307 |
Yu-En Hsu1, Szu-Chia Chen2,3,4,5, Jiun-Hung Geng6,7, Da-Wei Wu2,8, Pei-Yu Wu2,3, Jiun-Chi Huang2,3,4.
Abstract
The global pandemic of obesity and the increasing incidence of chronic respiratory diseases are growing health concerns. The association between obesity and pulmonary function is uncertain. Therefore, this study aimed to explore associations between changes in lung function and obesity-related indices in a large longitudinal study. A total of 9059 participants with no personal histories of asthma, smoking, bronchitis, or emphysema were enrolled from the Taiwan Biobank and followed for 4 years. Lung function was assessed using spirometry measurements including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC). Changes in FEV1/FVC (∆FEV1/FVC) between baseline and follow-up were calculated. The following obesity-related indices were studied: lipid accumulation product (LAP), body roundness index (BRI), conicity index (CI), body adiposity index (BAI), abdominal volume index (AVI), body mass index (BMI), waist-hip ratio (WHR), and waist-to-height ratio (WHtR). In multivariable analysis, the subjects with high BMI (p < 0.001), WHR (p < 0.001), WHtR (p < 0.001), LAP (p = 0.002), BRI (p < 0.001), CI (p = 0.005), BAI (p < 0.001), and AVI (p < 0.001) were significantly associated with a high baseline FEV1/FVC. After 4 years of follow-up, the subjects with high BMI (p < 0.001), WHR (p < 0.001), WHtR (p < 0.001), LAP (p = 0.001), BRI (p < 0.001), CI (p = 0.002), BAI (p < 0.001), and AVI (p < 0.001) were significantly associated with a low △FEV1/FVC. High obesity-related index values were associated with better baseline lung function and a rapid decrease in lung function at follow-up.Entities:
Keywords: Taiwan Biobank; follow-up; lung function; obesity-related index
Mesh:
Year: 2021 PMID: 34836307 PMCID: PMC8624262 DOI: 10.3390/nu13114055
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flowchart of study population.
Comparison of clinical characteristics among participants according to lung function.
| Characteristics | Normal | Obstructive |
|
|---|---|---|---|
| Age (year) | 50.9 ± 10.1 | 51.2 ± 10.5 | 0.275 |
| Male gender (%) | 20.9 | 18.2 | 0.003 |
| DM (%) | 4.5 | 3.8 | 0.115 |
| Hypertension (%) | 11.2 | 11.3 | 0.867 |
| Regular exercise habits (%) | 49.7 | 48.8 | 0.406 |
| SBP (mmHg) | 115.6 ± 17.5 | 116.7 ± 17.9 | 0.005 |
| DBP (mmHg) | 71.0 ± 10.6 | 71.6 ± 10.6 | 0.007 |
| Body height (cm) | 159.5 ± 7.5 | 159.3 ± 7.3 | 0.220 |
| Body weight (kg) | 60.6 ± 11.0 | 59.6 ± 10.5 | <0.001 |
| Waist circumference (cm) | 81.9 ± 9.5 | 81.1 ± 9.3 | <0.001 |
| Hip circumference (cm) | 95.3 ± 6.7 | 94.9 ± 6.6 | 0.007 |
| Laboratory parameters | |||
| Fasting glucose (mg/dL) | 94.9 ± 17.7 | 94.3 ± 17.3 | 0.139 |
| Hemoglobin (g/dL) | 13.4 ± 1.5 | 13.4 ± 1.4 | 0.037 |
| Triglyceride (mg/dL) | 106.8 ± 74.5 | 104.2 ± 69.1 | 0.105 |
| Total cholesterol (mg/dL) | 196.4 ± 35.3 | 195.9 ± 34.9 | 0.568 |
| HDL-cholesterol (mg/dL) | 56.1 ± 13.1 | 56.1 ± 13.0 | 0.853 |
| LDL-cholesterol (mg/dL) | 121.7 ± 31.3 | 121.0 ± 30.9 | 0.560 |
| eGFR (mL/min/1.73 m2) | 110.7 ± 25.5 | 111.5 ± 24.7 | 0.153 |
| Uric acid (mg/dL) | 5.24 ± 1.31 | 5.16 ± 1.30 | 0.006 |
| Lung function | |||
| FVC (L, baseline) | 2.68 ± 0.71 | 2.58 ± 0.73 | <0.001 |
| FVC (L, follow-up) | 2.48 ± 0.69 | 2.44 ± 0.70 | 0.003 |
| FEV1 (L, baseline) | 2.25 ± 0.61 | 1.31 ± 0.53 | <0.001 |
| FEV1 (L, follow-up) | 2.17 ± 0.63 | 2.10 ± 0.66 | <0.001 |
| FEV1/FVC (%, baseline) | 84.02 ± 6.21 | 50.55 ± 13.65 | <0.001 |
| FEV1/FVC (%, follow-up) | 87.86 ± 9.63 | 86.31 ± 12.18 | <0.001 |
| Obesity-related indices | |||
| BMI (kg/m2) | 23.8 ± 3.5 | 23.4 ± 3.4 | <0.001 |
| WHR (%) | 85.8 ± 6.7 | 85.3 ± 6.8 | 0.001 |
| WHtR (%) | 51.4 ± 6.0 | 51.0 ± 5.9 | 0.001 |
| LAP | 29.0 ± 27.5 | 27.6 ± 25.4 | 0.022 |
| BRI | 6.6 ± 1.8 | 6.4 ± 1.8 | <0.001 |
| CI | 1.222 ± 0.082 | 1.219 ± 0.084 | 0.037 |
| BAI | 29.4 ± 4.0 | 29.3 ± 3.9 | 0.185 |
| AVI | 13.7 ± 3.2 | 13.5 ± 3.1 | <0.001 |
Abbreviations. DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; FVC, forced vital capacity, FEV1, forced expiratory volume in 1 s; BMI, body mass index; WHR, waist–hip ratio; WHtR, waist-to-height ratio; LAP, lipid accumulation product; BRI, body roundness index; CI, conicity index; BAI, body adiposity index; AVI, abdominal volume index. Normal lung function was defined as FEV1/FVC ≥ 70% and FVC–predict ≥ 80%; obstructive lung function was defined as FEV1/FVC < 70%.
Determinants for baseline FEV1/FVC using univariable linear regression analysis.
| Characteristics | Univariable | |
|---|---|---|
| Unstandardized Coefficient β (95% CI) |
| |
| Age (per 1 year) | −0.053 (−0.090, −0.016) | 0.005 |
| Male (vs. female) | 1.154 (0.208, 2.100) | 0.017 |
| DM | 1.174 (−0.697, 3.044) | 0.219 |
| Hypertension | −0.341 (−1.539, 0.857) | 0.577 |
| Regular exercise habits | −0.078 (−0.835, 0.680) | 0.841 |
| SBP (per 1 mmHg) | −0.044 (−0.066, −0.023) | <0.001 |
| DBP (per 1 mmHg) | −0.063 (−0.099, −0.028) | 0.001 |
| Laboratory parameters | ||
| Fasting glucose (per 1 mg/dL) | 0.013 (−0.008, 0.035) | 0.230 |
| Hemoglobin (per 1 g/dL) | 0.227 (−0.033, 0.488) | 0.088 |
| Triglyceride (per 1 mg/dL) | 0.005 (0, 0.010) | 0.069 |
| Total cholesterol (per 1 mg/dL) | −0.004 (−0.014, 0.007) | 0.510 |
| HDL-cholesterol (per 1 mg/dL) | −0.006 (−0.035, 0.023) | 0.675 |
| LDL-cholesterol (per 1 mg/dL) | 7.781 × 10−5 (−0.012, 0.012) | 0.990 |
| eGFR (per 1 mL/min/1.73 m2) | −0.001 (−0.016, 0.014) | 0.854 |
| Uric acid (per 1 mg/dL) | 0.396 (0.106, 0.686) | 0.007 |
Values expressed as unstandardized coefficient β and 95% confidence interval (CI). Abbreviations are the same as in Table 1.
Association of obesity-related indices with baseline FEV1/FVC using multivariable linear regression analysis.
| Obesity-Related Indices | Multivariable | Adjusted R Square | |
|---|---|---|---|
| Unstandardized Coefficient β (95% CI) |
| ||
| BMI (per 1 kg/m2) | 0.303 (0.180, 0.426) | <0.001 | 0.6% |
| WHR (per 1%) | 0.123 (0.059, 0.186) | <0.001 | 0.5% |
| WHtR (per 1%) | 0.190 (0.120, 0.261) | <0.001 | 0.7% |
| LAP (per 1) | 0.245 (0.092, 0.397) | 0.002 | 0.5% |
| BRI (per 1) | 0.565 (0.336, 0.793) | <0.001 | 0.6% |
| CI (per 0.1) | 0.694 (0.210, 1.178) | 0.005 | 0.4% |
| BAI (per 1) | 0.263 (0.152, 0.374) | <0.001 | 0.6% |
| AVI (per 1) | 0.296 (0.161, 0.431) | <0.001 | 0.6% |
Values expressed as unstandardized coefficient β and 95% confidence interval (CI). Abbreviations are the same as in Table 1. Multivariable model: adjusted for age, sex, SBP, DBP, and uric acid (significant variables of Table 2).
Determinants for ∆FEV1/FVC using univariable linear regression analysis.
| Characteristics | Univariable | |
|---|---|---|
| Unstandardized Coefficient β (95% CI) |
| |
| Age (per 1 year) | 0.020 (−0.020, 0.061) | 0.325 |
| Male (vs. female) | −1.717 (−2.761, −0.674) | 0.001 |
| DM | −0.707 (−2.771, 1.357) | 0.502 |
| Hypertension | 0.347 (−0.975, 1.669) | 0.607 |
| Regular exercise habits | −0.207 (−1.043, 0.629) | 0.627 |
| SBP (per 1 mmHg) | 0.073 (0.050, 0.097) | <0.001 |
| DBP (per 1 mmHg) | 0.113 (0.073, 0.152) | <0.001 |
| Laboratory parameters | ||
| Fasting glucose (per 1 mg/dL) | −0.012 (−0.036, 0.012) | 0.317 |
| Hemoglobin (per 1 g/dL) | −0.246 (−0.534, 0.042) | 0.094 |
| Triglyceride (per 1 mg/dL) | −0.004 (−0.010, 0.002) | 0.169 |
| Total cholesterol (per 1 mg/dL) | 0.012 (0, 0.024) | 0.045 |
| HDL-cholesterol (per 1 mg/dL) | −0.021 (−0.053, 0.011) | 0.202 |
| LDL-cholesterol (per 1 mg/dL) | 0.006 (−0.008, 0.019) | 0.401 |
| eGFR (per 1 mL/min/1.73 m2) | 0.034 (0.018, 0.051) | <0.001 |
| Uric acid (per 1 mg/dL) | −0.248 (−0.568, 0.072) | 0.128 |
Values expressed as unstandardized coefficient β and 95% confidence interval (CI). Abbreviations are the same as in Table 1.
Association of obesity-related indices with ∆FEV1/FVC using multivariable linear regression analysis.
| Obesity-Related Indices | Multivariable | Adjusted R Square | |
|---|---|---|---|
| Unstandardized Coefficient β (95% CI) |
| ||
| BMI (per 1 kg/m2) | −0.280 (−0.409, −0.151) | <0.001 | 1.0% |
| WHR (per 1%) | −0.123 (−0.192, −0.055) | <0.001 | 0.8% |
| WHtR (per 1%) | −0.190 (−0.265, −0.115) | <0.001 | 1.1% |
| LAP (per 1) | −0.284 (−0.448, −0.120) | 0.001 | 0.9% |
| BRI (per 1) | −0.567 (−0.808, −0.325) | <0.001 | 1.0% |
| CI (per 0.1) | −0.855 (−1.385, −0.326) | 0.002 | 0.9% |
| BAI (per 1) | −0.272 (−0.392, −0.153) | <0.001 | 1.0% |
| AVI (per 1) | −0.306 (−0.449, −0.163) | <0.001 | 1.0% |
Values expressed as unstandardized coefficient β and 95% confidence interval (CI). Abbreviations are the same as in Table 1. Multivariable model: adjusted for age, sex, SBP, DBP, total cholesterol, and eGFR (significant variables of Table 4).